In the article by Moreaux et al entitled “CD200 is a new prognostic factor in multiple myeloma,” which appeared in the December 15, 2006, issue of Blood (Volume 108:4194-4197), the event-free survival values were not supported by the Kaplan-Meier plot of Figure 1C. We made a mistake using survival data of a preliminary version of that paper with a reduced patient cohort. With the cohort of 112 patients used in the paper, the median event-free survival (EFS) was 20 months for the CD200\textsuperscript{present} group and not reached for the CD200\textsuperscript{absent} group. These data could be improved with a recent update of patients’ survival. EFS is now 25 months for the CD200\textsuperscript{present} group and 44 months for the CD200\textsuperscript{absent} group.

Regarding ISS, it was not used to predict EFS in Greipp et al.\textsuperscript{20} In our study, events were defined as relapse, progressive disease, or death for autologous transplantation. For patients with allogenic transplantation, the EFS was censored 4 weeks after autologous transplantation. In our study, ISS proved to be predictive for both OS (P = 0.078) and EFS (P = 0.001) (new Figure 2). The median EFS was 47 months for stage 1, 25 months for stage 2, and 12 months for stage 3 (P = 0.001). CD200 expression and ISS staging were independently predictive for EFS when they were entered in a Cox-proportional hazard model with a 2.27 hazard ratio for CD200 expression and 1.91 for ISS staging.

Erratum

Figure 1C. Kaplan-Meier plot of the event-free survival in patients with CD200\textsuperscript{present} and CD200\textsuperscript{absent} MMCs.

Figure 2. Kaplan-Meier plots of the overall and event-free survivals in our cohort of 112 patients according to ISS stage.

Reference

Erratum in Moreaux et al. CD200 is a new prognostic factor in multiple myeloma.